Mumbai,
Nov 17: Pharma major, Cipla Ltd, today said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.
25mg/2mL, 0. 5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration
(USFDA) to market a generic version of Astrazeneca’s Pulmicort Respules. Cipla’s Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules® and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. The product is available for shipping immediately. Pulmicort Respules® and generic equivalents had U.S. sales of approximately $825M for the 12- month period ending September 2017, as reported by IMS Health. About Cipla Ltd. UNI
25mg/2mL, 0. 5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration
(USFDA) to market a generic version of Astrazeneca’s Pulmicort Respules. Cipla’s Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules® and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. The product is available for shipping immediately. Pulmicort Respules® and generic equivalents had U.S. sales of approximately $825M for the 12- month period ending September 2017, as reported by IMS Health. About Cipla Ltd. UNI
Post A Comment:
0 comments so far,add yours